Drug Trial Radar · NCT03833440
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
Last checked: Nov 20, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
114
Actual
Start
Oct 8, 2019
Primary completion
Oct 2024
Study completion Feb 2025
Sponsor
- Lead sponsor
- Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Research Hypothesis Lung cancer is the leading cause of cancer-related mortality in France and in western countries, accounting for more than 1.8 million new cases and 1.5 million deaths worldwide in 2012. Recent advances in the management of patients with Non-small Cell Lung Cancer Patients (NSCLC) include the use of therapies targeting oncogenes but a molecular alteration is currently found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over standard second-line chemotherapy both in squamous and non-squamous NSCLC. Unfortunately, this global overall survival benefit is driven by approximately 20% of the patient's population while a large majority of patients is in fact progressing in the first weeks of treatment. In the context of personalized medicine, innovative immunotherapy strategies in oncology are based on the principle of immune-contexture and require: * The identification of biomarkers for assessing the specific immune-contexture of each patient (microenvironment, tumors and effector cells) * The development of new treatments targeting their appropriate effector cells in monotherapy or combination treatments. The current PIONEER-Clinical study is aimed at assessing how to overcome resistance to ICIs monotherapies or ICI in combination with platinum-based chemotherapies, with experimental precision immunotherapies combined to Durvalumab in 2nd, 3rd or 4th line, in advanced NSCLC progressors patients after up to 18more than 6 w. of anti PD (L) 1. for ICIs monotherapies and after more than 12w. of anti PD(L)1 in combination with chemotherapies. Some supplementary blood and tissue samples are aimed at identification of personalized patients' biomarkers, correlation of them with the efficacy endpoints, in order to better understand mechanisms of resistance and improve their future treatment.
Conditions
- Non-small Cell Lung Cancer
Interventions
Durvalumab (MEDI4736)Drug
1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days c=cycle D= day
Monalizumab (IPH2201)Drug
1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days c=cycle D= day
Oleclumab (MEDI9447)Drug
3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days. c=cycle D= day
Ceralasertib (AZD6738)Drug
240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28. CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days c=cycle D= day
DOCETAXELDrug
75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days c=cycle D= day
SavolitinibDrug
600 mg QD 1 cycle = 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- the 12-week Disease Control RateTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Assistance Publique Hopitaux de Marseille
Marseille, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.